ImmuneRegen(R) licenses intellectual property from University of Pittsburgh

April 30, 2009

By hammersmith

[Source: The Associated Press/] –  ImmuneRegen BioSciences(R), a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), is pleased to announce that recent studies utilizing Homspera(R) confirm the compound stimulates a broad and long-lasting immune response in animals, as well as, provides protection against intracellular pathogens.

Specifically, the active component of Homspera, an agonist of the neurokinin-1 receptor (NK1R), among other immunostimulatory activities, promotes the activation and migration of skin dendritic cells (DCs) to lymph nodes to induce functional antigen specific cellular immunity, including CD4+ T-helper 1 cells (Th1) and CD8+ cytotoxic T-lymphocyte (CTL) responses. In addition, the NK1R agonist promotes the survival of DCs in vitro and in vivo resulting in prolonged effector immune responses. Together the adjuvant effects of the NK1R agonists are highly desired for effective immunization approaches. These studies were performed in the laboratories of Dr. Adriana Larregina, M.D., Ph.D., research assistant professor in the departments of Dermatology and Immunology, University of Pittsburgh School of Medicine.

For more information click here.